Lead Product(s) : Ceftriaxone,Edetate Calcium Disodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Venus Remedies Expands Reach with the Launch of Elores in Ecuador
Details : Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.
Product Name : Elores
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 14, 2023
Lead Product(s) : Ceftriaxone,Edetate Calcium Disodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ceftriaxone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Hasten Biopharmaceutic
Deal Size : Undisclosed
Deal Type : Acquisition
Hasten Acquires Commercial Rights In China For Roche’s Antibiotic Rocephin®
Details : Under the agreement, Hasten acquired Roche's China mainland rights for Rocephin® (ceftriaxone sodium), a long-acting, broad spectrum cephalosporin antibiotic, including the product's marketing authorization and certain intellectual property, including t...
Product Name : Rocephin
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 05, 2023
Lead Product(s) : Ceftriaxone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Hasten Biopharmaceutic
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
